Loading…
Employees: 6
Size Cypherpunk Technologies (CYPH) is a United States Health Care company (Financial Conglomerates) with a market value of $310M, the 3086th largest of 3,117 United States companies the cockpit tracks. Shares closed at $2.88 on 6 Nov 2026.
Performance Over six months the shares gained 142.0%, against -24.5% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Valuation It trades at 11.1× forward earnings.
Capital Return on invested capital runs 21.0 points below its cost of capital (10.3% WACC).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | $0 | -$5,000 | -$427,000 | -$415,000 |
| EBITDA | -$17.8M | -$36.5M | -$70.1M | -$86.6M | -$56.3M |
| Net income | -$877,000 | $4.82M | -$67.6M | -$81.4M | -$54.6M |
| Free cash flow | -$21.1M | -$43.9M | -$60.3M | -$43.8M | -$49.0M |
| Capital expenditure | $111M | $97.0M | $0 | $0 | $0 |
| Total debt | $38,000 | $38,000 | $266,000 | $262,000 | $678,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CYPH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | -10.1% | 5th highest of 21 |
| 6-month return | +142.0% | -24.5% | highest of 21 |
| Distance from 52-week high | -31.3% | -47.6% | 5th highest of 21 |
| Forward P/E | 11.1× | n/a | — |
| ROIC minus cost of capital | -21.0 pp | -48.0 pp | 5th highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cypherpunk Technologies CYPH | United States | $310M | +142% | n/a | n/a | 11.1× | n/a | n/a |
| Emergent BioSolutions EBS | United States | $312M | -27% | -18% | 5% | 16.1× | -0.1% | -13.7% |
| Community Health Systems CYH | United States | $312M | -21% | -8% | 7% | n/a | n/a | n/a |
| Ocugen OCGN | United States | $314M | -39% | -11% | -1,444% | n/a | n/a | n/a |
| X4 Pharmaceuticals XFOR | United States | $315M | -28% | -52% | -555% | n/a | n/a | n/a |
| Century Therapeutics IPSC | United States | $304M | -27% | -100% | n/a | n/a | n/a | n/a |
| Galectin Therapeutics GALT | United States | $317M | +50% | n/a | n/a | n/a | n/a | n/a |
| ASP Isotopes ASPI | United States | $318M | -61% | +573% | -312% | n/a | n/a | n/a |
| Kyverna Therapeutics KYTX | United States | $302M | -48% | n/a | n/a | n/a | n/a | n/a |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | n/a | n/a | n/a |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | n/a | n/a | n/a |
| Agenus AGEN | United States | $323M | +87% | +30% | 27% | n/a | n/a | n/a |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | n/a | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | n/a | n/a | n/a |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | n/a | n/a | n/a |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 18.7× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | n/a | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |